Movement Disorders (revue) - Analysis (France)

Index « Auteurs » - entrée « C. D. Marsden »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
C. Coutelle < C. D. Marsden < C. Falup-Pecurariu  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 2.
Ident.Authors (with country if any)Title
000631 (1994) Gilles Fénelon [France] ; Annaék Fève [France] ; Avindra Nath [Canada] ; Douglas E. Hobson [Canada] ; A. H. V. Schapira [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; M. S. Sandy [États-Unis] ; J. W. Langston [États-Unis] ; D. A. Di Monte [États-Unis] ; James J. Gaul [États-Unis]Letters to the editor
000672 (1989) J. A. Temlett [Suisse] ; N. P. Quinn [Royaume-Uni] ; P. G. Jenner [Suisse] ; C. D. Marsden [Royaume-Uni] ; E. Pourcher [France] ; A. Bonnet [France] ; Yves Agid [France] ; R. Markstein [Suisse] ; X. Lataste [Suisse]Antiparkinsonian activity of CY 208–243, a partial D‐1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's disease

List of associated KwdEn.i

Nombre de
documents
Descripteur
2Humans
11-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1AIDS Dementia Complex (complications)
1AIDS-Related Opportunistic Infections (complications)
1Aged
1Analgesics (therapeutic use)
1Animal
1Animals
1Antiparkinson agent
1Basal Ganglia Diseases (etiology)
1Blood Platelets (metabolism)
1CY 208–243
1Callitrichinae
1Chemotherapy
1Chromosome Deletion
1D1 Dopamine receptor
1DNA Mutational Analysis
1DNA, Mitochondrial (genetics)
1Dopamine Agents (therapeutic use)
1Dopamine agonist
1Dose activity relation
1D‐1 Agonist Drugs
1Experimental disease
1Female
1HIV-1
1Human
1Indoles (therapeutic use)
1Involuntary movement
1Levodopa (therapeutic use)
1Male
1Middle Aged
1Monkey
1Movement Disorders (etiology)
1NAD(P)H Dehydrogenase (Quinone) (deficiency)
1NAD(P)H Dehydrogenase (Quinone) (genetics)
1Nervous system diseases
1Parkinson Disease (blood)
1Parkinson Disease (drug therapy)
1Parkinson Disease (genetics)
1Parkinson Disease, Secondary (chemically induced)
1Parkinson disease
1Parkinson's Disease
1Phenanthridines (therapeutic use)
1Pyridines
1Subcutaneous administration
1Thalamic Diseases (etiology)
1Thalamic Nuclei
1Tolerance
1Toxoplasmosis, Cerebral (complications)
1Treatment

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "C. D. Marsden" 
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i  \
                -Sk "C. D. Marsden" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    C. D. Marsden
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024